Heart Disease News and Research

Latest Heart Disease News and Research

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.

5 Jan 2010

Fish oil supplement now available in water-soluble drink

Nordic Naturals, the industry leader in omega-3 fish oil, introduces Omega-3 Effervescent, an innovative way to enjoy fish oil supplementation via a water-soluble drink mix containing EPA and DHA in a delicious orange flavor.

5 Jan 2010

Philips DirectLife, a new interactive fitness program launched

Philips is delivering on their commitment to be the leader in health and well-being with the launch of Philips DirectLife, a new customized, interactive fitness program that offers a fun and simple solution to people eager to adopt a more active lifestyle.

5 Jan 2010

Article provides issues and challenges encountered by hospitals in implementing cooling program for post arrest patients

The European Resuscitation Council (ERC) and Elsevier's journal Resuscitation chose a randomized controlled study demonstrating a trend toward faster cooling and better control with Medivance's Arctic Sun® Temperature Management System as its featured "Article of the Month."

5 Jan 2010

Formatech selects ViroMed’s VM206 for Fillanthropy Program

Today, Formatech has selected the next candidate for its Fillanthropy Program: ViroMed’s VM206 therapeutic cancer vaccine. Under the Fillanthropy Program, Formatech will donate the services required to aseptically fill and finish one lot of the vaccine to support ViroMed’s upcoming clinical trials.

5 Jan 2010

World Heart changes its jurisdiction of incorporation to the U.S. State of Delaware

World Heart Corporation, a developer of mechanical circulatory support systems, today announced that effective January 1, 2010, it has changed its jurisdiction of incorporation from the federal jurisdiction of Canada to the State of Delaware in the United States of America through a plan of arrangement (the "Arrangement").

5 Jan 2010

NQF endorses 70 measures to improve gathering of clinical electronic data

As an incremental step toward wider use of electronic data platforms to measure, report, and improve quality, the National Quality Forum (NQF) has endorsed 70 measures that combine data from two or more common electronic sources such as administrative claims, pharmacy and laboratory systems, and registries.

5 Jan 2010

January issue of Chest presents new studies on COPD

A new study shows that poor lung function during adolescence and through midlife may be influenced by several factors, including birth weight, height, and gender.

5 Jan 2010

GE Healthcare and Intel expand sales and marketing agreement for Intel Health Guide in the U.K.

GE Healthcare, a unit of GE, and Intel Corporation (NASDAQ:INTC) announced today that they have expanded their sales and marketing agreement for the Intel Health Guide to include the United Kingdom. GE Healthcare already markets the Intel Health Guide in the United States.

5 Jan 2010

Vitamin C reverses accelerated aging due to Werner's syndrome

A new research discovery published in the January 2010 print issue of the FASEB Journal suggests that treatments for disorders that cause accelerated aging, particularly Werner's syndrome, might come straight from the family medicine chest. In the research report, a team of Canadian scientists show that vitamin C stops and even reverses accelerated aging in a mouse model of Werner's syndrome, but the discovery may also be applicable to other progeroid syndromes.

5 Jan 2010

Elevated diabetes risk associated with smoking cessation, but lifestyle changes can help combat risk

Cigarette smoking is a well-known risk factor for type 2 diabetes, but new research from Johns Hopkins suggests that quitting the habit may actually raise diabetes risk in the short term.

5 Jan 2010

Global scientific meeting on osteoporosis and osteoarthritis

IOF WCO-ECCEO10 will be the largest global scientific meeting devoted exclusively to osteoporosis and osteoarthritis in 2010. We look forward to welcoming you in Florence next spring!

5 Jan 2010

Study shows running shoes exert greater stress on knees, hips and ankles

Knee osteoarthritis (OA) accounts for more disability in the elderly than any other disease. Running, although it has proven cardiovascular and other health benefits, can increase stresses on the joints of the leg.

5 Jan 2010

Changes needed in orthopedic training programs, but restrictions and generational differences compromise learning experience

Changes are needed in the programs that train orthopedic surgeons to ensure these doctors are adequately trained, according to a study by researchers at Hospital for Special Surgery (HSS) in New York City.

5 Jan 2010

Anti-inflammatory prescription drug reduces the risk of common skin cancer in humans

A widely-available anti-inflammatory prescription drug can reduce the risk of a common skin cancer in humans, according to a researcher at Stanford's School of Medicine.

5 Jan 2010

ART publishes impressive data on its bioresorbable stent

Arterial Remodeling Technologies (“ART”) announced today that it has disclosed impressive in vivo and in vitro data related to its bioresorbable stent platform—data that validates the Company’s approach to simultaneously balance biocompatibility, biomechanics and bioresorption in a bioresorbable PLA (polylactic acid) stent without altering healing by drug elution from the stent platform.

5 Jan 2010

New chemoprevention therapy for skin cancer

People with the heritable disorder of the skin called Gorlin syndrome who are genetically predisposed to develop basal cell carcinoma of the skin may have a new chemoprevention therapy on the horizon.

5 Jan 2010

VELCADE sNDA receives FDA approval

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

5 Jan 2010

Study examines relationship between parental vaccine refusal and risk of varicella infection in children

Children of parents who refuse vaccines are nine times more likely to get chickenpox compared to fully immunized children, according to a new study led by a vaccine research team at Kaiser Permanente Colorado's Institute for Health Research.

5 Jan 2010

Book reveals new evidence of obesity-causing chemicals in American diet

The New American Diet, a groundbreaking new book by Men’s Health Editor-at-Large Stephen Perrine and Heather Hurlock, reveals the powerful new scientific evidence about obesity-causing chemicals lurking in the American diet – chemicals that disrupt our hormonal systems ultimately triggering substantial weight gain.

5 Jan 2010